NEW YORK, Sept. 26 - Dresdner Kleinwort Wasserstein has begun covering a handful of “special niche” genomic and proteomic companies, the financial company said on Wednesday.

The coverage, which will be led by analyst Charles C. Duncan, will include Celgene, CuraGen, Exelixis, Human Genome Sciences, Millennium Pharmaceuticals, Myriad Genetics, Tularik, and Vertex Pharmaceuticals. These all were rated a “Buy,” the company said in a statement. Two more companies, Celera Genomics and Sangamo BioSciences, were rated an “Add.”